Genetic Variation in Platelet Aggregation
The aim of the study is to test whether genetic variation in the alpha 2A adrenergic receptor affects diurnal variation in platelet aggregation.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Genetic Variation in Platelet Aggregation|
- percentage platelet aggregation [ Time Frame: Within 120minutes of sample collection ] [ Designated as safety issue: No ]We will compare the percentage platelet aggregation to 2µM epinephrine between haplotype 4 family participants and other haplotype families
- Percentage platelet aggregation to collagen and ADP [ Time Frame: within 120 minutes of sample collection ] [ Designated as safety issue: No ]We will compare the percentage platelet aggregation to collagen and ADP between haplotype 4 participant and other haplotype families.
- Percentage platelet aggregation after cold pressor test [ Time Frame: within 120 minutes of sample collection ] [ Designated as safety issue: No ]We will compare percentage platelet aggregation of different agonist after cold pressor test between haplotype 4 participants and other haplotype families.
Biospecimen Retention: Samples With DNA
Blood samples for DNA and plasma/serum for subsequent biomarker analysis if required.
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Normal healthy volunteers
There is a marked diurnal fluctuation in the occurrence of acute myocardial infarction and sudden death, with peak incidences occurring in the early morning. Platelet aggregation has also been shown to increase in the early morning. The investigators will test the hypothesis that ADRA2A genetic variation, specifically haplotype 4, affects platelet aggregation. The investigators will compare diurnal platelet aggregation in haplotype 4 subjects with subjects in the other haplotype families. In addition, the investigators will compare platelet aggregation after the cold pressor test in haplotype 4 with the other haplotype families.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01576536
|Contact: Michael C Stein, MBChBfirstname.lastname@example.org|
|Contact: Abiodun O Adefurin, MBChB||901 857 email@example.com|
|United States, Tennessee|
|the Vanderbilt University General Clinical Research Center||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Michael C Stein, MBChB 615-936-3420 firstname.lastname@example.org|
|Contact: Abiodun Adefurin, MBChB 901 857 2032 email@example.com|
|Principal Investigator: Michael Stein, MBChB|
|Principal Investigator:||Michael Stein, MBChB||Vanderbilt University|